Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03151629 · ClinicalTrials.gov registry record
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
A clinical trial of Prostate Cancer, sponsored by Prostate Cancer Clinical Trials Consortium.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT03151629: Recruiting study of Prostate Cancer, sponsored by Prostate Cancer Clinical Trials Consortium.
NCT03151629 is a study of Prostate Cancer that is actively recruiting participants, run by Prostate Cancer Clinical Trials Consortium. The registered enrollment target is 5,000 participants, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03151629, a study of Prostate Cancer, is actively recruiting participants, sponsored by Prostate Cancer Clinical Trials Consortium.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen
Conditions Studied
Interventions
- OTHER Standard of Care
Study Locations (20)
Illinois
- University of Illinois at Chicago - Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
- University of Chicago - Chicago
- Kishwaukee Cancer Center - DeKalb
- Delnor Cancer Center - Geneva
- Warrenville Cancer Center - Warrenville
Florida
- University of Florida - Gainesville
- Mayo Clinic Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Alabama
- University of Alabama-Birmingham - Birmingham
- University of Alabama- Tuscaloosa - Tuscaloosa
California
- University of California - Los Angeles - Los Angeles
- University of California San Diego - San Diego
Georgia
- Morehouse School of Medicine - Atlanta
- Emory Winship Cancer Institute - Atlanta
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
- Chesapeake Urology Associates - Towson
Connecticut
- Yale University - New Haven
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2032-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03151629
The ClinicalTrials.gov registry entry for NCT03151629 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The listed sponsor is Prostate Cancer Clinical Trials Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care is the first listed.
NCT03151629 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03151629 about?
NCT03151629 is a clinical study titled "International Registry for Men With Advanced Prostate Cancer (IRONMAN)". Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and...
What is the current status of trial NCT03151629?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2017-07-21. Estimated completion is 2032-01.
What conditions does trial NCT03151629 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03151629?
The interventions under investigation include: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT03151629?
This trial is sponsored by Prostate Cancer Clinical Trials Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03151629 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.